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Abstract
Neuroblastoma is an embryonal extracranial solid tumor originating from undifferentiated 
neural crest cell and it is the most common among children. Neuroblastoma is highly het-
erogeneous, and on these bases different outcomes are observed across the subtypes. Its 
clinical impact (~13% of all pediatric cancer mortality) has made this aggressive malignancy 
the focus of a considerable translational research effort. New insights into tumor biology are 
leading to the development of novel therapeutic approaches, which include small-molecule 
inhibitors as well as epigenetic approaches, noncoding-RNA, and cell-based immunologic 
therapies. Recently, chromatin immunoprecipitation with high-throughput sequencing 
and RNA-sequencing studies have demonstrated that epigenetic changes contribute to the 
aggressive pathophysiology of pediatric neuroblastoma disease. Epigenetic abnormalities 
are feature of human cancer cells and the epigenetic alterations may be the key toward 
tumorigenesis. In particular, the increase of deacetylation has been involved in epigeneti-
cally mediated tumor-suppressor gene silencing. In addition, several studies evaluated the 
5-methylcytosine (5 mC) distribution patterns, which distinguish cancer cells from normal 
cells, and how CpG methylation contributes to the oncogenic phenotype.
In particular, histone changes and DNA methylation are fundamental biological pro-
cesses representing versatile candidates for pharmacological manipulation with impor-
tant therapeutic advantages.
Keywords: neuroblastoma, epigenetics, histone marks, DNA methylation, proteasome 
inhibitors
1. Introduction
Neuroblastoma is an embryonal extracranial solid tumor originating from undifferentiated 
neural crest cell and it is the most common among children. Neuroblastomas are highly 
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
heterogeneous, and on these bases different outcomes are observed across the subtypes 
from the spontaneous regression, asymptomatic tumors, as well as metastasized tumors to 
rapid progression and resistance to therapy. Its clinical impact (~13% of all pediatric cancer 
mortality) has made this aggressive malignancy the focus of a considerable translational 
research effort. Recent literature suggests that alterations in gene transcription programs 
drive disease-specific gene expression, thus highlighting the significance of transcription as 
a major mechanism for driving tumor growth and neoplastic transformation. In this chapter, 
the sophisticated language of the epigenetic code emerges as promising target for cancer 
therapy. It is generally accepted that epigenetic abnormalities are feature of human cancer 
cells and that epigenetic alterations may be the key toward tumorigenesis. Briefly, in eukary-
otic nuclei, DNA is wrapped around an octameric histone (H) unit, which is composed of 
H2A, H2B, H3, and H4. This basic structure known as a nucleosome is repeated along the 
double-stranded DNA, with a fifth type of histone (the linker histone H1) bridging together 
consecutive nucleosomes (Figure 1). Based on the level of compaction, we can distinguish 
two main forms of chromatin: the euchromatin is the transcriptionally active form character-
ized by permissive marks such as the acetylation of different lysine residues; the heterochro-
matin is the transcriptionally silent configuration and contains repressive epigenetic marks 
[1]. These forms differ biochemically with respect to the presence of specific markers at the 
histone tails (see Figure 2) and to the binding of structural proteins.
Gene transcription in eukaryotic utilizes multiple mechanisms and it is mainly regulated by four 
families of the ATP-dependent chromatin-remodeling complexes (switching defective/sucrose 
non-fermenting = SWI/SNF; imitation-switch = ISWI; Mi-2/nucleosome remodeling and histone 
deacetylation = Mi-2/NuRD; inositol 80 = INO80), named “remodelers” [3–6]. A growing body 
Figure 1. Schematic representation of the nucleosome. The nucleosome core is composed of a histone octamer [(H2A-
H2B)×2, (H3-H4)×2]. The DNA double helix is wrapped around (~1.7 times) the histone octamer. With nuclease 
digestion, 146 bps of DNA are tightly associated with the nucleosome but ~200 bps of DNA in total are associated with 
the nucleosome [2].
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of evidence suggests that the dysregulation of chromatin remodelers such as activating muta-
tion, homozygous deletion, epigenetic silencing, and overexpression has a crucial role in cancer 
development and in its progression [7–10]. Advances in genomic technologies have allowed a 
better understanding of genomic signatures underlying human cancer.
1.1. Histone modifications
Histone tails are subject to different post-translational modifications (PTMs), including acety-
lation, methylation, and phosphorylation. The best characterized chromatin PTM is the histone 
acetylation, which results from a dynamic balance of the activity of two enzymatic families: 
histone acetyl-transferases (HATs) and histone deacetylases (HDACs) [11, 12]. Alterations in 
the balance of these enzyme activities lead to a disruption of cellular integrity and are fre-
quently observed in different tumors. In particular, the increase of deacetylation has been 
involved in epigenetically mediated tumor-suppressor gene silencing; thus, HDACs represent 
a promising class of anticancer drug targets [13] (Figure 2).
Methylation of histone proteins is generally found on arginine and lysine residues. Three dif-
ferent forms of methylation have been observed on the lysine residues (mono-, di-, and tri-
methylation), whereas arginine can be mono-methylated and symmetrically or asymmetrically 
di-methylated; these modifications play different functions in gene transcription [14] (Figure 2). 
In fact, methylation of histones can either increase or decrease gene transcription, depending on 
which amino acids on the histones are methylated, and how many methyl groups are attached.
For example, trimethylation of lysine 4 on histone H3 (H3K4me3) is abundant at active gene 
promoter, whereas trimethylation of lysine 9 on histone H3 (H3K9me3) is associated with tran-
scriptionally repressed gene promoters [15]. Histone methylation process is catalyzed by three 
distinct families of methyltransferase enzymes namely the SET-domain containing protein 
Figure 2. All histones are subject to post-transcriptional modifications (PTMs) which mainly occur on the histone tails. 
The main PTMs are depicted in this figure: acetylation (ס), methylation (●), phosphorylation (□) and ubiquitination (Ub). 
The number under each amino acid [K = lysine (Lys), R = arginine (Arg) and S = serine (Ser)] represents its position in 
the sequence (Adapted from  Zhang and Reinberg, 2001) [16]. In addition, the position K4, K9, K27, K36 and  K79 can be 
mono-/di-/ or trimethylated.
Epigenetic Approaches in Neuroblastoma Disease Pathogenesis
http://dx.doi.org/10.5772/intechopen.69566
129
family, the non-SET domain protein family, and the protein arginine methyltransferase family 
1 (PRMT1) [17]. Changes in histone methylation status take part in various physiological and 
pathological processes, including cancer.
1.2. DNA methylation
The understanding of DNA methylation contribution to cancer-specific alterations and the 
exact consequences of these mutations, in the key steps of tumorigenesis, will represent a useful 
tool in epigenetics therapy. In mammals, DNA methylation occurs predominantly at cytosine in 
CpG islands, and their methylation acts as a relatively stable gene-silencing mechanism. Over 
the last 40 years, several studies evaluated the 5-methylcytosine (5 mC) distribution patterns, 
which distinguish cancer cells from normal cells, and how CpG methylation contributes to the 
oncogenic phenotype.
DNA methylation is regulated by a family of DNA methyltransferases (DNMTs) which catalyze 
the transfer of methyl groups from S-adenosyl-L-methionine to the 5′ position of cytosine bases 
in the CpG dinucleotide. DNMT3A and DNMT3B establish new DNA methylation patterns 
early in development [19].
During replication, the original DNA methylation pattern is mainly maintained by DNMT1 
activity, which prefers hemi-methylated DNA over non-methylated DNA as a substrate 
[20] and it is therefore responsible for the maintenance of methylation patterns during cell 
division, with some participation by DNMT3A and DNMT3B [21]. DNMT1, DNMT3A, and 
DNMT3B are often overexpressed in various cancers and they may contribute to the abnormal 
hypermethylation [18, 22].
In this view, it is interesting to note that the global DNA hypomethylation [18–20], the 
abnormal hypermethylation in promoter CpG islands [23–25] and the exact mutagenesis of 
sequences containing 5 mC [26, 27] may occur simultaneously suggesting that altered homeo-
stasis of epigenetic mechanisms is central to the evolution of human cancer and plays an 
active role in increasing chromosomal fragility.
2. Epigenetics landscape in mammalian development
Notwithstanding the neuroblastoma, tumorigenesis arise from the disrupted development of 
neural crest precursors, no single genetic or epigenetic mutation has been found after the DNA 
and RNA sequencing of over 1000 cases [28]. Recently, chromatin immunoprecipitation with 
high-throughput-sequencing and RNA-sequencing studies have demonstrated specific epigen-
etic patterns which distinguish neuroectoderm, neural crest, and more mature neural states, 
since a cardinal property of neural stem cells (NSCs) is their ability to adopt multiple fates upon 
differentiation [29]. Fascinating studies focused their attention on the epigenome as indicator of 
cell fate, and numerous observations highlight significant alterations within chromatin struc-
ture during mammalian development [30, 31]. In this frame, the developmental epigenetic regu-
lation is the most deeply documented in the embryonic stem cell (ESC) research. Even though 
many promoters of developmental genes in ESCs contain permissive as well as repressive 
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epigenetic marks, they are transcriptionally silent and maintained in a transcriptionally silent 
state until differentiation [32]. Analogously, the NSCs differentiation is a unidirectional process 
tightly regulated to ensure the acquisition of specific neuronal phenotypes [33]. A novel chro-
matin modification pattern known as “bivalent domains” may explain these processes. Mainly, 
genes that are active in cells throughout development originally have active promoters which 
are characterized by the presence of the bivalent histone modification pattern consisting of 
H3K4me3 (permissive mark), trimethylation of lysine (K) 27 on histone H3 (H3K27me3, repres-
sive mark), and a lack of DNA methylation. Genes enriched for K27me3 in ESC include those 
involved in early embryonic development, organogenesis, and cell fate decisions. In fact, genes 
that become transcriptionally active lose much of their polycomb-mediated repressive H3K27 
methylation, conversely those that become silenced lose their H3K4 methylation or increases 
the polycomb-mediated repressive chromatin mark [32, 34]. However, recent works suggest 
that the loss of H3K27me3 is not sufficient to lead the increased transcription of all genes.
In the same direction, it has been shown that during the differentiation of ESC-derived NSCs, 
to immature GABAergic interneurons, all non-GABAergic promoters maintain the H3K27me3 
repressive monovalency mark, whereas GABAergic promoters maintain the H3K4me3 mark 
(permissive monovalency) [29].
However, little is still known about the overall genomic distribution of K4 rather than K27 
methylation in ESCs; the hypothesis is that bivalent domains consist of large regions of K27 
methylation which hid smaller regions of K4 methylation. This bivalence condition is usually 
lost during ESC differentiation and in the differentiated cells [32].
Besides histone modification, the DNA methylation is equally essential for mammalian develop-
ment and it is also linked to tumorigenesis [35, 36]. Unlike bivalent domains, cytosine methyla-
tion provides a methylated genome which can self-protect from environment changes due to the 
ability to repress specific promoters [37]. Among the three active DNA cytosine methyltransfer-
ases, identified in human and mouse [38, 39], the DNMT1 is responsible for copying the paren-
tal-strand methylation pattern onto the daughter strand after each round of DNA replication; 
DNMT3A and DNMT3B are strongly expressed in ESCs where they are essential for the de novo 
methylation and in maintaining methylation patterns [36, 40]. In 2003, it has been reported that 
the inactivation of both DNMT3A and DNMT3B results in progressive loss of methylation in 
various repeats and single-copy genes in ESCs. Moreover, the introduction of DNMT isoforms 
into highly demethylated mutant ESCs showed that the DNMT3A, DNMT3A2, and DNMT3B1 
restore genomic methylation patterns, whereas DNMT1 and DNMT3B3 failed to restore DNA 
methylation patterns due to their inability to catalyze de novo methylation in vivo [41].
3. Novel therapeutic approaches in neuroblastoma
3.1. Epigenetic therapy
Since neuroblastoma is a complex disease, driven by multiple genetic and epigenetic altera-
tions, it is subject of intensive ongoing genomic research. In particular, during tumor initiation 
and progression the epigenome goes through multiple alterations. Promoter hypermethylation 
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of tumor-suppressor genes [42], together with promoter methylation of several DNA repair 
genes and histone modifications [43], is commonly observed in cancer cells. Neuroblastoma 
is frequently associated with numerous genetic alterations and in this regard it has been 
reported that the restored expression of the zinc-finger transcription factor castor (human cas-
tor gene: CASZ1) inhibits cell proliferation in vitro and decreases tumor growth in vivo [44]. In 
addition, the expression of CASZ1 appears significantly decreased in aggressive phenotype of 
patients with unfavorable prognoses [45], thus indicating CASZ1 as a tumor-suppressor gene 
in neuroblastoma tumor. However, the absence of consistent CpG methylation of CASZ1 in 
neuroblastoma excludes a gene-silencing mechanism due to DNA methylation [46]; on the 
contrary, it seems that trichostatin A, a histone deacetylase inhibitors, induces CASZ1 expres-
sion in neuroblastoma cells [46], suggesting an epigenetic mechanism mainly dependent on 
histone regulation. In addition, histone modifications may affect the recruitment of transcrip-
tion factors and of other components of the transcription machinery, thereby contributing 
to aberrant gene expression [21]; notably, altered histone modifications have been found in 
neuroblastoma tumors and have been correlated to tumor aggressiveness [45, 47]. Despite 
this evidence, the epigenetic changes, which contribute to the aggressive pathophysiology of 
neuroblastoma, are still poorly known. In this frame, preclinical studies have demonstrated 
that the DNA methylation appears to play a role in angiogenesis inhibitor thrombospondin-1 
(TSP-1) regulation [48]. Neuroblastoma growth might be closely related to angiogenesis, since 
the angiogenesis inhibitors downregulation has been observed in highly malignant neuro-
blastoma cells and the administration of antiangiogenesis agents successfully inhibits neu-
roblastoma growth in vivo [49, 50]. In this regard, Yang and colleagues tested the efficacy of 
5-Aza-dC (a demethylating agent) to restore the TSP-1 transcription in the TSP-1-negative 
neuroblastoma cell lines confirming that the silencing of this gene was triggered by a methyla-
tion process (Figure 3) [48]. Therefore, demethylating agents may be effective candidates for 
neuroblastoma-affected children.
Because epigenetic changes caused by DNA methylation are critical for the initiation and 
for the cancer progression, it has been also demonstrated that aberrant splicing of DNMTs 
is frequently exhibited in cancer cells [22, 51]. Notably, it has been suggested that high levels 
of truncated DNMT3B7 isoform alter DNA methylation and might be related to embryonic 
development and a less aggressive clinical neuroblastoma phenotype [52]. To test this hypoth-
esis, Ostler and colleagues forced the expression of DNMT3B7 isoform in neuroblastoma cells 
to evaluate its effects on DNA methylation, tumor growth, and angiogenesis. They observed 
an increase of global DNA methylation, the decrease of aggressive neuroblastoma growth, and 
the suppression of angiogenesis, respectively, consistent with a nonmalignant phenotype [52].
3.2. Combined therapy with proteasome inhibitor
The presence of cancer stem cell population in the neuroblastoma increases the migratory prop-
erties of cancer cells, and this is a major concern in cancer therapeutics since the relapse of tumor 
and resistance to therapy are due to the self-renewing cancer cells [53, 54]. Doxorubicin (Dox), 
a Food and Drug Administration (FDA)-approved chemotherapeutic agent widely used in 
numerous cancer type, would benefit neuroblastoma patients and lead to better outcomes [55]. 
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However, Dox induces nuclear factor-κB (NF-κB) activation which is believed to contribute to 
the development of chemoresistance [56]; thus, a viable option in cancer therapy could be the 
inhibition of NF-κB activation to overcome the chemoresistance. Among various biological sys-
tems exploited to obtain therapeutic benefits, the ubiquitin-proteasome system has been associ-
ated with tumor cell survival [57]. Notably, pharmacological inhibition of proteasome activity 
by small-molecule inhibitors shows anti-tumor efficacy in various cancer types [57]; proteasome 
activity has been also reported to be involved in NF-κB activation by promoting the degradation 
of its inhibitor IκBα [58].
Therefore, in order to improve therapeutic outcomes, the ability of Ixazomib to suppress 
neuroblastoma cell proliferation and to induce cell apoptosis has been recently reported. 
Ixazomib is a selective second-generation proteasome inhibitor able to enhance the Dox cyto-
toxicity (Figure 4) and capable to inhibit Dox-induced NF-κB activation [59]. Li and colleagues 
demonstrated the anti-tumor efficacy of Ixazomib in combination with Dox corroborating the 
hypothesis that combination therapies of proteasome inhibitors and chemotherapeutic agents 
will achieve better outcomes in neuroblastoma therapy. Similar results were also obtained 
using another second-generation proteasome inhibitor, the Carfilzomib [60] indicating the 
relevance of proteasome machinery in the therapeutic strategy for treating neuroblastoma 
patients.
Figure 3. Reinstatement of TSP-1 after treatment with 5-Aza-dC. (A) TSP-1 gene expression levels were detected 
by RT-PCR analysis in NBL-W-S cells treated with vehicle or 1 or 5 μM of 5-Aza-dC for 60h; (B) time-dependent 
re-expression of TSP-1 following exposure to exposed to 1 μM of 5-Aza-dC; (C) Western blot analysis of TSP-1 expression 
after treatment with 5-Aza-dC (image from Yang et al., 2003) [48].
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4. Clinical trials for neuroblastoma
Since epigenetic dysregulation is a fundamental process underlying the pathogenesis of pedi-
atric brain tumors, the use of epigenetic modifiers is currently under evaluation in the early 
phase of clinical trials. Epigenetic modifiers FDA approved mainly comprise two classes of 
agents: HDACs inhibitors (Vorinostat, Romidepsin, and Valproic Acid) and DNA methyla-
tion inhibitors (5-azacytidine and Deoxyazacytidine (Decitabine)).
Figure 4. Cell viability results after Dox plus ixazomib (1 or 5 μM) for 48 h; data showed that Ixazomib enhances dox-
induced cytotoxicity in different types of Neuroblastoma cell lines. (a–f) IMR-32 (a) NGP (b) NB-19 (c) SH-SY5Y (d) 
SK-N-AS (e) and LA-N-6 (f) cells were seeded in 96-well plates (Li et al., 2016) [59].
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In November 2015, a phase I trial aiming to test the toxicity of Vorinostat in combination with 
Isotretinoin and to see how well they work in treating patients with high risk of refractory or 
recurrent neuroblastoma has been completed. Results showed that Vorinostat may stop the 
growth of tumor cells by blocking some of the enzymes needed for cell growth; in addition, 
Isotretinoin may help Vorinostat to work better making tumor cells more sensitive to the 
drug. The deduction aroused from results has been that Vorinostat together with Isotretinoin 
may be an effective treatment for neuroblastoma [61]. Simultaneously, another study tested 
the efficacy of Vorinostat and Iobenguane I 131 (131-I MIBG) to treat patients with resistant or 
relapsed neuroblastoma. The results demonstrated that the association of Vorinostat together 
with 131-I MIBG kills more tumor cells, since 131-I MIBG is a radioactive drugs which carry 
radiation directly to the tumor cells [62, 63].
A phase I study on Decitabine with Doxorubicin in children with neuroblastoma, and other 
solid tumors, revealed dose-limiting hematologic toxicities which were experienced by chil-
dren [64]. It is still controversial whether drug toxicity and response rates to HDAC and DNA 
methylation inhibitors are strictly determined by the somatic tumor genotype or whether 
heritable germline factors may also contribute to the final outcomes [65]. Thus, it will be cru-
cial to establish the optimal dose and treatment schedule of available drugs, especially con-
sidering heavily pretreated patients. To this end, biomarkers of drug efficacy should be used 
to ascertain whether pharmacological agents, such as epigenetic modifiers, have the predicted 
biologic effect. Subsequently, tissue availability should be essential for pathologic assessment 
of the response whenever new epigenetically targeted agents are introduced into the clinical 
setting.
Currently, a cohort observational study is ongoing and still recruiting participants at the 
St. Jude Children’s Research Hospital of Memphis, Tennessee (US). The aim of the study 
is to characterize the molecular, cellular, and genetic properties of primary and metastatic 
neuroblastoma, osteosarcoma, and other solid tumors. The isolated cells will be used for 
gene expression analysis, genomic analysis by single nucleotide polymorphism (SNP), 
comparative genomic hybridization, and next-generation sequencing. Epigenetic studies 
will be also performed investigating at the methylation profile of these cells [66].
At present, there are approximately 500 ongoing clinical trials for neuroblastoma using dif-
ferent therapeutic strategies [67], and only two of these comprise an epigenetic approach [68]. 
By contrast, as regard the use of proteasome inhibitors there are approximately 80 and 130 
ongoing clinical trials, respectively, on Ixazomib and Carfilzomib, to test the side effects and 
best dose in different cancer conditions [69], but none of these is exclusive for patients affected 
by neuroblastoma disease [70].
5. Taking advantage of neuroblastoma cells: versatile model for 
neurobiology studies
The ability to produce in vitro cultures of neuronal cells has been crucial for the understanding 
of central nervous system (CNS) function regulation. The neuronal cell ability to  proliferate, 
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as well as to differentiate, makes them an excellent in vitro system for several studies. The 
 secondary cell lines derived from neuronal tumors are usually immortalized; they have the 
advantage to grow easily, to give unlimited proliferation in vitro, and to minimize variabil-
ity between cultures. Cell lines are often induced to display a more neuronal phenotype by 
manipulations of the culture conditions, for example, through the addition of specific differ-
entiation factors such as retinoic acid.
Neuroblastoma SH-SY5Y cells retain the ability to differentiate into neuronal cell types by 
all-trans-retinoic acid treatment which causes substantial alterations in the abundance of dis-
tinct G protein subunits [71]. In this regard, they have been used to examine the relationships 
between proliferation, differentiation, and apoptosis and this feature has been useful for the 
development of therapeutic strategies.
Neuroblastoma cells are extensively used for testing neurotoxicity of putative drugs, and also 
for understanding neuroplasticity phenomena, such as those evoked by the exposure of drugs 
of abuse. In particular, studies conducted in human neuroblastoma SH-SY5Y cells demon-
strated that ethanol exposure influences epigenetic regulation through histone acetylation, 
hence regulating DNA transcription at specific portions of the genome [72]. Drugs of abuse 
have also been associated with proteasome inhibition which seems to be a key player in epi-
genetic mechanisms underlying the accumulation of oxidatively damaged histones [73]. In 
this frame, recent finding showed that ethanol exposure reduced intracellular 20S proteasome 
chymotrypsin-like activity in SH-SY5Y cells [74], in agreement with findings obtained in liver 
and brain demonstrating that ethanol decreased proteasome activity by interfering with 20S-
CP (core particle) and 19S-RP (regulatory particle) assembly [75, 76]. By contrast, cocaine has 
been reported to exert an opposite effect on the 20S proteasome, since the chymotrypsin-like 
activity [74] increases.
Although some studies failed to demonstrate the correlation between the increased risk of 
neuroblastoma in offspring and parental alcohol or tobacco use [77, 78], neuroblastoma cell 
cultures currently represent a useful tool for the study of neuroplasticity phenomena.
6. Highlights and conclusions
In the last decades, a great variety of novel therapeutic strategies have become available for 
cancer. These therapies often are very specific and effective only in subsets of cancer patients, 
thus increasing the needs for the clinician to choose specific therapeutic strategy. This situa-
tion exerts a notable impact on the methods in diagnostic tumor pathology, since it requires 
precise tumor characterization to support the clinical management of the individual case. In 
this frame, epigenetic changes are important for the initiation and progression of cancers, 
including neuroblastoma. New insights into tumor biology are driving the development of 
novel therapeutic approaches which include small-molecule inhibitors as well as epigenetic 
approaches. The reversible nature of epigenetic modifications, the better knowledge of mech-
anisms underlying these changes and the consequent alterations of regulatory networks, may 
provide an interesting opportunity for the development of clinically relevant therapeutics. In 
particular, histone changes and DNA methylation are fundamental biological processes and 
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they seem to be promising candidates for pharmacological manipulation with encouraging 
therapeutic advantages.
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Appendices
Histone H (H1, H2A, H2B, H3, H4)
K lysine
R arginine
S serine
SWI/SNF switching defective/sucrose non-fermenting
ISWI imitation-switch
Mi-2/NuRD Mi-2/nucleosome remodeling and histone deacetylation
INO80 inositol 80
PTMs posttranslational modifications
HATs histone acetyl-transferases
HDACs histone deacetylases
tri-methylation me3
PRMT1 protein arginine methyltransferases
5mC 5-methylcytosine
DNMTs DNA methyltransferases (DNMT1, DNMT3A, DNMT3A2, DNMT3B, 
DNMT3B1, DNMT3B3, DNMT3B7)
NSCs neural stem cells
ESCs embryonic stem cells
TSP-1 angiogenesis inhibitor thrombospondin-1
Dox Doxorubicin
NF-κB Nuclear factor kappa B transcription factor
IκBα Nuclear factor kappa B inhibitor, alpha
CP proteasome core particle
RP proteasome regulatory particle
PRMT1 protein arginine methyltransferases family 1
CASZ1 zinc-finger transcription factor castor (human castor gene)
SNP Single nucleotide polymorphism
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